Topic: autoimmune disease
China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.
VISTA represents a novel checkpoint regulator that can be targeted by both agonists and antagonists to trigger opposing therapeutic T-cell effects.
Two years after hiving off its healthcare assets into a subsidiary, Intrexon is bringing those assets back into the fold.
Rheos Medicines has sealed a near $800 million biobucks deal with Swiss major Roche to seek out and develop new meds in immunometabolism.
Alexion bought Syntimmune last year based on data showing that SYNT001 could lower both IgG levels and IgG circulating immune complexes.
All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.
Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.
More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.
A Brigham and Women's team found a microRNA in the microbiome that increases when MS peaks. Giving it back to mice as a treatment relieved symptoms.
Pandion and Astellas inked a deal to discover, develop and market bispecific drugs for Type 1 diabetes and other autoimmune diseases of the pancreas.